SCHEMBL6031396

SCHEMBL6031396

O=C(Cn1cc(Nc2ncnc3cc(OCCCN4CCC(CCO)CC4)ccc23)nn1)Nc1cccc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 14/20 0.55
AURKB Q96GD4 8/20 0.53
KDR P35968 8/20 0.53
PDGFRB P09619 2/20 0.52
PDGFRA P16234 2/20 0.52
FLT1 P17948 2/20 0.52
FLT4 P35916 2/20 0.52
CDK1 P06493 1/20 0.52
EGFR P00533 4/20 0.51
CSK P41240 2/20 0.51
IGF1R P08069 1/20 0.51
FGFR1 P11362 1/20 0.51
SRC P12931 1/20 0.51
FGFR2 P21802 1/20 0.51
FGFR4 P22455 1/20 0.51
FGFR3 P22607 1/20 0.51
CDK2 P24941 1/20 0.51
JAK3 P52333 1/20 0.51
PTK2 Q05397 1/20 0.51
BRAF P15056 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029185 0.95 AURKA (0.59) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6028435 0.92 AURKA (0.56) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6027522 0.92 AURKA (0.57) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6090503 0.91 AURKA (0.56) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6030625 0.90 AURKA (0.56) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6028491 0.89 AURKA (0.55) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6027886 0.89 AURKA (0.60) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6026562 0.89 KDR (0.60) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6027774 0.89 AURKA (0.56) AURKAAURKBKDRPDGFRBPDGFRA
SCHEMBL6027367 0.86 AURKA (0.73) AURKAAURKBKDRPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US claimed
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US disclosed
EP-1644361-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS Astrazeneca AB (SE) 2006-04-12 EP disclosed
WO-2004113324-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885KDR 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.